Agendia raises 25 million euros
Amsterdam – Agendia BV has raised €25 million in a fourth financing round. ING, one of the largest bank insurers, becomes a shareholder of Agendia, a molecular diagnostics company that develops and provides highly specific cancer diagnostic tests for pathologists, oncologists, clinicians and patients through its central service laboratory. Other investors include Van Herk Biotech, Gilde HealthCare Partners and Global Life Sciences Ventures. In February 2007, Agendia was the first company to receive a 510K clearance from the US FDA for it’s MammaPrint breast cancer prognosis test on fresh-frozen tumour tissue under the newly defined IVDMIA regulations (in vitro diagnostics multivariate index assay).
The product is developed to predict the likelihood of breast cancer recurrence within 5-10 years.